Hycamtin — CareFirst (Caremark)
Small Cell Lung Cancer (SCLC)
Initial criteria
- Authorization may be granted for treatment of small cell lung cancer.
Reauthorization criteria
- Authorization may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months